Fresenius Medical Care AG & Co. KGaA provided earning guidance for 2021. The company anticipates significant negative impact on 2021 net income from accelerated COVID-19 related excess mortality of dialysis patients. Against this backdrop and based on the currently available information and status of analysis, for 2021, the company anticipates revenue growth of up to mid-single digits and assume net income before potential restructuring measures to decline by up to 25%. In order to avoid any misunderstanding, the basis for the 25% is the high level of 2020 net income before special items, this means before the impairment charge. By 2025, the company projects to grow revenues in the mid-single-digit percentage range, along with high single-digit net income growth.